ATE317226T1 - Behandlung der schizophrenie mit ampakinen und neuroleptika - Google Patents

Behandlung der schizophrenie mit ampakinen und neuroleptika

Info

Publication number: ATE317226T1
Authority: AT; Austria
Prior art keywords: schizophrenia; treatment; ampakines; neuroleptics; relates
Prior art date: 1997-10-27

Application number

AT98957382T

Other languages

English (en)

Inventor

Steven A Johnson

Gary A Rogers

Gary S Lynch

Original Assignee

Cortex Pharma Inc

Univ California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-27

Filing date

1998-10-26

Publication date

2006-02-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22050462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE317226(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-10-26 Application filed by Cortex Pharma Inc, Univ California filed Critical Cortex Pharma Inc

2006-02-15 Application granted granted Critical

2006-02-15 Publication of ATE317226T1 publication Critical patent/ATE317226T1/de

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Hydrogenated Pyridines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT98957382T 1997-10-27 1998-10-26 Behandlung der schizophrenie mit ampakinen und neuroleptika ATE317226T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US6362797P	1997-10-27	1997-10-27

Publications (1)

Publication Number	Publication Date
ATE317226T1 true ATE317226T1 (de)	2006-02-15

Family

ID=22050462

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98957382T ATE317226T1 (de)	1997-10-27	1998-10-26	Behandlung der schizophrenie mit ampakinen und neuroleptika

Country Status (14)

Country	Link
US (1)	US6166008A (de)
EP (1)	EP1026950B1 (de)
JP (1)	JP2001520978A (de)
CN (1)	CN1281335A (de)
AT (1)	ATE317226T1 (de)
AU (1)	AU745641B2 (de)
BR (1)	BR9814106A (de)
CA (1)	CA2306817A1 (de)
CY (1)	CY1105557T1 (de)
DE (1)	DE69833451T2 (de)
DK (1)	DK1026950T3 (de)
ES (1)	ES2258825T3 (de)
PT (1)	PT1026950E (de)
WO (1)	WO1999021422A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2138533C (en)	1992-07-24	2009-04-14	Gary S. Lynch	Drugs that enhance synaptic responses mediated by ampa receptors
GB0102841D0 (en) *	2001-02-05	2001-03-21	Novartis Ag	Organic compounds
US20050020582A1 (en) *	2001-05-25	2005-01-27	Prusiner Stanley B	Optically active compounds clearing malformed proteins
US20040229898A1 (en) *	2001-05-25	2004-11-18	The Regents Of The University Of California	Cyclic bis-compounds clearing malformed proteins
US7320785B2 (en) *	2001-08-10	2008-01-22	The Rockefeller University	Compositions and methods for modulation of DARPP-32 phosphorylation
AU2004204814B2 (en) *	2003-01-13	2009-10-08	Cortex Pharmaceuticals, Inc.	Method of treating cognitive decline due to sleep deprivation and stress
WO2005013961A1 (en) *	2003-07-17	2005-02-17	Eli Lilly And Company	Combination therapy for treatment of cognitive disorders or psychoses
NZ527142A (en) *	2003-07-23	2006-03-31	Douglas Pharmaceuticals Ltd	A stable suspension formulation
CA2536975A1 (en) *	2003-08-28	2005-03-17	Nitromed, Inc.	Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
GB0325175D0 (en) *	2003-10-28	2003-12-03	Novartis Ag	Organic compounds
JP2007519733A (ja) *	2004-01-26	2007-07-19	コーテックスファーマシューティカルズインコーポレーティッド	アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
US8415298B2 (en)	2004-06-21	2013-04-09	The Board Of Trustees Of The Leland Stanford Junior University Of Stanford	Administration of FGF2 for treamtent of anxiety
US20060063707A1 (en) *	2004-09-17	2006-03-23	Lifelike Biomatic, Inc.	Compositions for enhancing memory and methods therefor
JP2008514612A (ja) *	2004-09-23	2008-05-08	ミシャロウ、アレクサンダー	対抗適応を誘発することにより神経伝達物質系を調節する方法
US7396829B2 (en) *	2005-02-24	2008-07-08	Nitromed, Inc.	Nitric oxide enhancing diuretic compounds, compositions and methods of use
ME02051B (me)	2005-04-13	2015-05-20	Astex Therapeutics Ltd	Derivati hidroksibenzamida i njihova primena kao inhibitora hsp90
KR20060119373A (ko) *	2005-05-20	2006-11-24	엘지전자 주식회사	컴퓨터 시스템과 시스템 소프트웨어 설치방법 및 휴대용컴퓨터의 소프트웨어 설치방법
EP1951908B1 (de)	2005-11-12	2013-08-07	The Board of Trustees of The Leland Stanford Junior University	Verfahren in zusammenhang mit diagnose und behandlung von depressionen
WO2007060144A2 (en) *	2005-11-22	2007-05-31	Neurosearch A/S	Novel quinoxaline derivatives and their medical use
US7754725B2 (en)	2006-03-01	2010-07-13	Astex Therapeutics Ltd.	Dihydroxyphenyl isoindolymethanones
US20080176793A1 (en) *	2006-09-18	2008-07-24	The Regents Of The University Of California	Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects
WO2008044054A2 (en)	2006-10-12	2008-04-17	Astex Therapeutics Limited	Hydroxy-substituted benzoic acid amide compounds for use in therapy
JP5410285B2 (ja)	2006-10-12	2014-02-05	アステックス、セラピューティックス、リミテッド	医薬化合物
EP2073807A1 (de)	2006-10-12	2009-07-01	Astex Therapeutics Limited	Pharmazeutische kombinationen
GB0620259D0 (en)	2006-10-12	2006-11-22	Astex Therapeutics Ltd	Pharmaceutical compounds
EP2073803B1 (de)	2006-10-12	2018-09-19	Astex Therapeutics Limited	Pharmazeutische kombinationen
EP2073802A1 (de)	2006-10-12	2009-07-01	Astex Therapeutics Limited	Pharmazeutische kombinationen
WO2008128166A1 (en) *	2007-04-13	2008-10-23	Concert Pharmaceuticals Inc.	Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
US20090006902A1 (en) *	2007-06-29	2009-01-01	International Business Machines Corporation	Methods, systems, and computer program products for reporting fru failures in storage device enclosures
KR20100045507A (ko)	2007-08-10	2010-05-03	코텍스 파마슈티칼스, 인크.	글루타메이트성 시냅스 반응을 향상시키기 위한 비시클릭 아미드
US8119632B2 (en)	2007-08-10	2012-02-21	Cortex Pharmaceuticals, Inc.	Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8071914B2 (en) *	2007-12-26	2011-12-06	Noboru Oshima	Heating apparatus
GB0806527D0 (en)	2008-04-11	2008-05-14	Astex Therapeutics Ltd	Pharmaceutical compounds
JP2012516845A (ja) *	2009-02-02	2012-07-26	コーテックスファーマシューティカルズ，インコーポレイテッド	グルタミン酸作動性シナプス反応を増強するための二環式アミド誘導体
PT105083A (pt)	2009-04-28	2011-07-25	Univ De Coimbra	Processo para cultura de células estaminais neurais baseado nas ampacinas e/ou outros moduladores de receptores glutamatérgicos ionotrópicos, composições e seu uso em condições do sistema nervoso central
EP2544688B1 (de)	2010-03-02	2016-09-07	President and Fellows of Harvard College	Verfahren und zusammensetzungen zur behandlung des angelman-syndroms
EP2801377B1 (de)	2011-03-04	2019-08-07	The Regents of The University of California	Hydrogel enthaltend Zellen zur lokalen Freisetzung von Wachstumsfaktoren zur Rückgewinnung der Bewegungsfähigkeit nach einem Schlaganfall
US8822464B2 (en)	2011-11-28	2014-09-02	Boehringer Ingelheim International Gmbh	N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) *	2011-12-05	2014-06-03	Boehringer Ingelheim International Gmbh	Compounds
US8846948B2 (en)	2011-12-13	2014-09-30	Boehringer Ingelheim International Gmbh	Compounds
US8796467B2 (en)	2011-12-13	2014-08-05	Boehringer Ingelheim International Gmbh	Compounds
US8937176B2 (en)	2011-12-14	2015-01-20	Boehringer Ingelheim International Gmbh	Compounds
US8883789B2 (en)	2011-12-14	2014-11-11	Boehringer Ingelheim International Gmbh	Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8716277B2 (en)	2011-12-14	2014-05-06	Boehringer Ingelheim International Gmbh	Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8889677B2 (en)	2012-01-17	2014-11-18	Boehringer Ingellheim International GmbH	Substituted triazoles useful as mGlu5 receptor modulators
EP2854836B1 (de)	2012-06-05	2018-04-04	The Board of Trustees of The Leland Stanford Junior University	Ncam-peptidmimetika zur behandlung von depression
LT3781561T (lt)	2018-04-18	2024-07-10	Constellation Pharmaceuticals, Inc.	Metilą modifikuojančių fermentų moduliatoriai, kompozicijos ir jų naudojimas
WO2019226491A1 (en)	2018-05-21	2019-11-28	Constellation Pharmaceuticals, Inc.	Modulators of methyl modifying enzymes, compositions and uses thereof
PE20220562A1 (es)	2019-07-24	2022-04-13	Constellation Pharmaceuticals Inc	Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8908085D0 (en) *	1989-04-11	1989-05-24	Lundbeck & Co As H	New therapeutic use
US5312819A (en) *	1990-08-20	1994-05-17	Sandoz Ltd.	Pharmaceutical compositions comprising clozapine and a radical scavenger
US5447948A (en) *	1992-05-07	1995-09-05	Yale University	Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
GB9507230D0 (en) *	1995-04-07	1995-05-31	Inst Of Psychiatry	Novel method
US5650409A (en) *	1995-06-02	1997-07-22	Cortex Pharmaceuticals, Inc.	Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5773434A (en) *	1995-08-30	1998-06-30	Gary A. Rogers	Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
US5736543A (en) *	1996-04-03	1998-04-07	The Regents Of The University Of California	Benzoxazines for enhancing synaptic response

1998
- 1998-10-26 PT PT98957382T patent/PT1026950E/pt unknown
- 1998-10-26 US US09/179,341 patent/US6166008A/en not_active Expired - Lifetime
- 1998-10-26 AU AU13658/99A patent/AU745641B2/en not_active Ceased
- 1998-10-26 JP JP2000517599A patent/JP2001520978A/ja active Pending
- 1998-10-26 DE DE69833451T patent/DE69833451T2/de not_active Expired - Lifetime
- 1998-10-26 EP EP98957382A patent/EP1026950B1/de not_active Revoked
- 1998-10-26 WO PCT/US1998/022707 patent/WO1999021422A1/en not_active Ceased
- 1998-10-26 BR BR9814106-6A patent/BR9814106A/pt not_active Application Discontinuation
- 1998-10-26 DK DK98957382T patent/DK1026950T3/da active
- 1998-10-26 AT AT98957382T patent/ATE317226T1/de active
- 1998-10-26 ES ES98957382T patent/ES2258825T3/es not_active Expired - Lifetime
- 1998-10-26 CA CA002306817A patent/CA2306817A1/en not_active Abandoned
- 1998-10-26 CN CN98812086A patent/CN1281335A/zh active Pending
2006
- 2006-05-04 CY CY20061100571T patent/CY1105557T1/el unknown

Also Published As

Publication number	Publication date
EP1026950A1 (de)	2000-08-16
JP2001520978A (ja)	2001-11-06
DE69833451D1 (de)	2006-04-20
DE69833451T2 (de)	2006-09-28
CY1105557T1 (el)	2010-07-28
US6166008A (en)	2000-12-26
EP1026950A4 (de)	2004-07-07
WO1999021422A1 (en)	1999-05-06
DK1026950T3 (da)	2006-06-26
CA2306817A1 (en)	1999-05-06
AU1365899A (en)	1999-05-17
BR9814106A (pt)	2000-10-03
ES2258825T3 (es)	2006-09-01
AU745641B2 (en)	2002-03-28
HK1030338A1 (en)	2001-05-04
PT1026950E (pt)	2006-06-30
CN1281335A (zh)	2001-01-24
EP1026950B1 (de)	2006-02-08

Publication	Publication Date	Title
ATE317226T1 (de)	2006-02-15	Behandlung der schizophrenie mit ampakinen und neuroleptika
DE60024588D1 (de)	2006-01-12	Substituierte porphyrine und deren therapeutische verwendungen
DE69429524D1 (de)	2002-01-31	Aminocyclohexylester und ihre anwendung
DK0751939T5 (da)	2004-11-08	Naphthylamider som centralnervesystemmidler
TR200002773T2 (tr)	2001-11-21	Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
DE69813898D1 (de)	2003-05-28	Substituierte porphyrinen
ATE256671T1 (de)	2004-01-15	2-phenyl-substituierte 1-(n-phenylaminoalkyl)- piperazin-derivate
WO2003103575A3 (en)	2004-02-26	Compounds, compositions, and methods
MA28010A1 (fr)	2006-07-03	Derives de piperazine et leur utilisation comme agents therapeutiques
PA8478501A1 (es)	2000-05-24	Compuestos heterociclicos como inhibidores de enzimas de rotamasa
PT1044197E (pt)	2006-07-31	Carboxamidas de piridilalcano, -alceno e -alcino substituidas por piperidinilo como agentes citostaticos e imunossupressores
DE69616480D1 (de)	2001-12-06	Piperidinderivate als neurokininantagonisten
DE69724811D1 (de)	2003-10-16	Pentafluorobenzensulfonamide und analoge
ATE293448T1 (de)	2005-05-15	Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
ATE288747T1 (de)	2005-02-15	Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ID25856A (id)	2000-11-09	Senyawa-senyawa baru
CA2284551A1 (en)	1998-10-08	New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
DE60304695D1 (de)	2006-05-24	7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
TR200101149T2 (tr)	2001-10-22	Dış retina bozukluklarının tedavisi.
PT1000046E (pt)	2004-04-30	Derivados de piperazina activos no trato urinario inferior
MX9205374A (es)	1993-03-01	Piridinil-amino-1h-indoles, 1h-indazoles, 2h-indazoles, benzo(b)tiofenos y 1,2-benzo-isotiazoles sustituidos, un procedimiento para su preparacion y su utilizacion como medicamentos.
ATE330604T1 (de)	2006-07-15	Behandlung von manischen erkrankungen
ES2196820T3 (es)	2003-12-16	Derivados de pirido(2,3-b)indolizina y aza-analogos de la misma; ligandos especificos de crf 1.
TR200000916T2 (tr)	2000-07-21	İkameli piperidin türevleri.

Legal Events

Date	Code	Title	Description
2006-12-15	UEP	Publication of translation of european patent specification	Ref document number: 1026950 Country of ref document: EP

Date

Code

Title

Description

2006-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1026950

Country of ref document: EP